SG Americas Securities LLC Trims Position in CryoPort, Inc. $CYRX

SG Americas Securities LLC decreased its holdings in shares of CryoPort, Inc. (NASDAQ:CYRX) by 87.2% in the 1st quarter, Holdings Channel.com reports. The institutional investor owned 15,252 shares of the company’s stock after selling 103,471 shares during the quarter. SG Americas Securities LLC’s holdings in CryoPort were worth $126,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently added to or reduced their stakes in CYRX. Basepoint Wealth LLC acquired a new stake in CryoPort during the 4th quarter worth approximately $34,000. Tower Research Capital LLC TRC raised its stake in shares of CryoPort by 300.1% during the second quarter. Tower Research Capital LLC TRC now owns 5,833 shares of the company’s stock worth $44,000 after purchasing an additional 4,375 shares during the last quarter. Creative Planning acquired a new stake in shares of CryoPort during the second quarter worth $96,000. Quadrature Capital Ltd purchased a new position in CryoPort in the 4th quarter valued at $97,000. Finally, State of Wyoming increased its stake in CryoPort by 30.2% in the 2nd quarter. State of Wyoming now owns 14,218 shares of the company’s stock valued at $106,000 after buying an additional 3,301 shares during the period. Institutional investors and hedge funds own 92.90% of the company’s stock.

Insider Buying and Selling at CryoPort

In other news, CFO Robert Stefanovich sold 169,427 shares of CryoPort stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $16.27, for a total transaction of $2,756,577.29. Following the completion of the sale, the chief financial officer directly owned 109,850 shares in the company, valued at approximately $1,787,259.50. This trade represents a 60.67% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Edward J. Zecchini sold 33,600 shares of the business’s stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $14.47, for a total value of $486,192.00. Following the sale, the insider directly owned 109,719 shares in the company, valued at $1,587,633.93. This trade represents a 23.44% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 227,641 shares of company stock valued at $3,622,515. Corporate insiders own 9.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on CYRX shares. Wall Street Zen upgraded shares of CryoPort from a “sell” rating to a “hold” rating in a research note on Monday, May 11th. KeyCorp increased their price target on shares of CryoPort from $15.00 to $17.00 and gave the stock an “overweight” rating in a report on Wednesday, May 20th. Jefferies Financial Group set a $13.50 price objective on shares of CryoPort in a research report on Monday, June 8th. Craig Hallum lifted their price objective on CryoPort from $15.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday, June 3rd. Finally, Weiss Ratings upgraded CryoPort from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, May 6th. Eight investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, CryoPort has an average rating of “Moderate Buy” and an average price target of $15.11.

CryoPort Price Performance

NASDAQ:CYRX opened at $16.17 on Monday. CryoPort, Inc. has a fifty-two week low of $6.69 and a fifty-two week high of $16.73. The stock has a market cap of $814.97 million, a PE ratio of 11.98 and a beta of 1.88. The firm’s fifty day simple moving average is $14.61 and its 200-day simple moving average is $11.16.

CryoPort (NASDAQ:CYRX) last announced its quarterly earnings data on Monday, May 4th. The company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.03). The company had revenue of $47.80 million during the quarter, compared to analyst estimates of $44.86 million. CryoPort had a net margin of 41.57% and a negative return on equity of 7.92%. Equities analysts anticipate that CryoPort, Inc. will post -0.85 earnings per share for the current year.

CryoPort Company Profile

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.